澳華內鏡(688212.SH):目前在主攻的海外市場是歐洲,AQ-200已完成MDR檢測並獲得CE註冊證書
格隆匯8月31日丨澳華內鏡(688212.SH)於2023年8月15日-8月31日召開業績説明會、參加路演活動等等,互動問答環節中,就“公司上半年海外市場增速在30%以上,後續海外的推廣計劃?”
公司回覆稱,公司目前在主攻的海外市場是歐洲。公司有個德國子公司過去幾年表現比較穩健,可以對接公司的一些產品維修服務。目前公司現在海外市場還是非常初步的階段,公司AQ-200已完成MDR檢測並獲得CE註冊證書,但是海外推廣策略目前與國內還不一樣,仍處於以各價位段產品共同發力的模式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.